Clinical Trial Search

Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…

Primary: Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12 — -89.5; -25.0 mm Hg

Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44

Primary: Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. — -23; 31 Percentage change in fibrotic…

Primary: Recruitment as Assessed by Number of Participants Who Enrolled to the Study — 29; 13 Participants

Primary: Increase, Stability of, or Decrease in the Decline of Diastolic Function as Reflected by the Global Early Myocardial Relaxation (E') Velocity — -0.06; -0.21 cm/sec…

Primary: Change From Baseline in Peak VO2 as Measured by Cardiopulmonary Exercise Test (CPET) — 1.00; 0.39 mL/kg/min — p=0.5506

Primary: Change in Peak Oxygen Consumption (Peak VO2) — 1.35; 0.08 mL/kg/min

Primary: Incidence of Adverse Events (AEs) — 10; 7; 11; 4 Participants

Primary: Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE) — 88.9; 90.5; 68.4 percentage of participants

Primary: Percentage of Participants Achieving A Clinical Response — 45; 22 Participants

Primary: Change From Baseline in Post-exercise Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30 — -60.6963 millimeters of mercury (mmHg)

Primary: HsCRP — -1.1; 0.5; -1.3; -0.3 mg/L

Primary: Left Ventricular Mass — 155.1680523; 129.5013331 gram

Primary: Whole-Muscle Protein Synthesis — 0.004; 0.015 %/hr

Primary: LVEF — 65.4; 64.7; 62.2 percentage of blood in left ventricle — p=<0.0005

Primary: Peak VO2 — 14.5; 12.9 ml/kg/min

Primary: Phosphocreatine Recovery — 0.74 correlation coefficient — p=0.02

Primary: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 — 10; 43 Participants — p=<0.0001